Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial With 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

NCT04375267 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT04375267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04375267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial With 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Lead sponsor
Vastra Gotaland Region
Phase
Phase 1
Overall status
Completed
Start date
April 23, 2020
Completion date
June 30, 2024
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical trial, phase i, mesothelioma, neuroendocrine tumors, thymoma